Taysha Gets FDA Fast-Track for Rett Syndrome Treatment
By Dean Seal
Taysha Gene Therapies said regulators have granted fast-track designation for TSHA-102, a gene transfer therapy in clinical evaluation for the neurodevelopmental disorder Rett Syndrome.
The Dallas-based clinical-stage company said the special status from the U.S. Food and Drug Administration has been granted after encouraging initial data from the first adult patient in Canada dosed with TSHA-102. A second patient is set to be dosed in the current quarter.
The FDA's fast-track designation facilitates the development and expedites the review of drugs that treat serious or life-threatening conditions and fill unmet medical needs.
TSHA-102 also has received orphan-drug and rare-pediatric-disease designations from the FDA, as well as orphan-drug designation from the European Commission.
Shares climbed 8% to $2.40 in premarket trading.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
August 24, 2023 08:37 ET (12:37 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now